Project description:In this study, we performed comprehensive genomic, transcriptomic, proteomic, and phosphorylation analysis of tumor tissues and paired normal adjacent tissues (NATs) of AEG. we describe integrative proteogenomic analyses of the largest cohort to date of AEG samples that focused particularly on novel and clinically actionable insights revealed in the proteome and Phosphorylation modifications. The data may improve current knowledge about AEG and contribute to its diagnosis, prognosis and drug development.

2022-11-14 | PXD030725 | Pride

Integrated Proteogenomic Characterization of Adenocarcinoma of the esophagogastric junction

2022-11-14 | PXD030667 | Pride

m6A full transcriptome map of human adenocarcinoma of esophagogastric junction

Project description:Here we systematically analyze the modification pattern of m6A mRNA in adenocarcinoma at the esophagogastric junction.In adenocarcinoma of esophagogastric junction samples, a total of 4775 new m6A peaks appeared, and 3054 peaks disappeared. The unique m6A-related genes in adenocarcinoma of esophagogastric junction are related to cancer-related pathways. There are hypermethylated or hypomethylated m6A peaks in AEG in differentially expressed mRNA transcripts. This study preliminarily constructed the first m6A full transcriptome map of human adenocarcinoma of esophagogastric junction. This has a guiding role in revealing the mechanism of m6A-mediated gene expression regulation.

2022-02-18 | GSE189874 | GEO

Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma.

Project description: Not available

| S-EPMC6911151 | biostudies-literature

P-280Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): Randomized, phase 3 KEYNOTE-18

Project description: Not available

| S-EPMC4984067 | biostudies-literature